Chronic Utricaria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Chronic Utricaria Pipeline Insights 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Utricaria pipeline landscape. It covers the Chronic Utricaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Utricaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chronic Utricaria Pipeline. Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Utricaria Pipeline Report
• On January 13, 2026- Novartis Pharmaceuticals initiated a clinical study was designed to evaluate the pharmacokinetics, safety and efficacy of ligelizumab in children from 12 to < 18 years of age, with chronic spontaneous urticaria (CSU). The participants were treated with ligelizumab as an add-on therapy to approved doses of H1 antihistamines (H1AH) following the guideline on treatment of CSU.
• On January 08, 2026- Blueprint Medicines Corporation conducted a phase 2 study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
• On January 06, 2026- Evommune Inc. announced a study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
• DelveInsight's Chronic Utricaria pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Chronic Utricaria treatment.
• The leading Chronic Utricaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical and others.
• Promising Chronic Utricaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Desloratadine, Xolair® (Omalizumab), Povorcitinib, EVO756 and others.

Stay ahead with the most recent pipeline outlook for Chronic Utricaria. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Chronic Utricaria Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chronic Utricaria Pipeline Report also highlights the unmet needs with respect to the Chronic Utricaria.

Chronic Utricaria Overview
Chronic Urticaria (CU) is a persistent skin condition characterized by the recurring appearance of itchy hives (welts) and sometimes deeper swelling known as angioedema that lasts for 6 weeks or more, and can continue for months or even years. It's driven by an immune-mediated response involving mast cells releasing histamine and other inflammatory mediators, although in many cases the exact trigger remains unknown. CU significantly impacts quality of life due to its chronic itch, discomfort, sleep disruption, and emotional stress.

Chronic Utricaria Emerging Drugs Profile
• CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria.

• Povorcitinib - Incyte Corporation
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.

• Briquilimab: Jasper Therapeutics
Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.

The Chronic Utricaria Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Utricaria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Utricaria Treatment.
• Chronic Utricaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Utricaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Utricaria market

Explore groundbreaking therapies and clinical trials in the Chronic Utricaria Pipeline. Access DelveInsight's detailed report now! @ https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Utricaria Companies
Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical and others.

Chronic Utricaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Utricaria Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Chronic Utricaria Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Utricaria Pipeline Report
• Coverage- Global
• Chronic Utricaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical and others.
• Chronic Utricaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Desloratadine, Xolair® (Omalizumab), Povorcitinib, EVO756 and others.
• Chronic Utricaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Utricaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chronic Utricaria Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Urticaria or Hives : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Urticaria or Hives - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
9. Mid Stage Products (Phase II)
10. Povorcitinib - Incyte Corporation
11. Early Stage Products (Phase I)
12. Briquilimab: Jasper Therapeutics
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Chronic Urticaria or Hives Key Companies
16. Chronic Urticaria or Hives Key Products
17. Chronic Urticaria or Hives - Unmet Needs
18. Chronic Urticaria or Hives - Market Drivers and Barriers
19. Chronic Urticaria or Hives - Future Perspectives and Conclusion
20. Chronic Urticaria or Hives Analyst Views
21. Chronic Urticaria or Hives Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.